Summary of childhood and adolescent patients with HSTCL, 2017 to 2024
| Patient number . | Reference . | Age (y)/sex . | Comorbidities . | Treatment . | Transplant type . | Outcome . |
|---|---|---|---|---|---|---|
| 1 | 14 | 10/M | None | HR BFM induction, CR Reinduction with IT MTX, vincristine, idarubicin, asparaginase, and dexamethasone after relapse 4 mo later | N/A | Alive |
| 2 | 15 | 5/F | Unknown | ICE + 1 additional unspecified line of therapy, AD | Allo, CR | Alive |
| 3 | 15 | 8/M | Unknown | ICE + 1 additional unspecified line of therapy, AD | Allo, CR | Relapsed at unknown time posttransplant Died of HSTCL |
| 4 | 15 | 9/M | Unknown | ICE + 1 additional unspecified line of therapy, CR | Allo, CR | Alive |
| 5 | 15 | 4/F | Unknown | ICE plus 1 additional unspecified line of therapy, CR | Allo, CR | Alive |
| 6 | 16 | 10/M | None | Inter-B-NHL 2010 Group C1 (no rituximab), AD ICE, AD GEM-P with daratumumab, AD UKALL regimen B, AD | N/A | Died of HSTCL |
| 7 | 17 | 10/F | None | 4-drug B-ALL induction followed by bendamustine and maintenance with lenalidomide and celecoxib, CR | N/A | Alive |
| 8 | 17 | 16/M | None | CHOEP, AD ICE + bortezomib, AD | N/A | Died of HSTCL |
| 9 | 18 | 3/F | History of short stature, microcephaly | Tokyo Children’s Cancer Study Group L09-1603 induction, AD FLAG, CR | Allo, CR | Alive |
| 10 | 19 | 3/F | History of mixed phenotype acute leukemia | ICE, alemtuzumab, radiation therapy, AD | N/A | Died at 107 d of follow-up |
| 11 | 19 | 4/M | None | None | N/A | Died |
| 12 | 19 | 21/M | None | ICE, CR | Allo, CR | Lost to follow-up after transplant |
| 13 | 20 | 17/F | None | Splenectomy, ICE, PD Pralatrexate-CHP, PR | Allo, CR | Died after transplant due to complications from human metapneumovirus pneumonia |
| 14 | 21 | 14/F | Turner syndrome, Crohn disease (prior 6-MP treatment) | ICE, CR | Allo, CR | Alive 1 y after transplant |
| 15 | 22 | 15/F | Crohn disease (prior 6-MP, MTX treatment) | ICE, PR | N/A | Died 2 mo after diagnosis of disseminated HSTCL and multiorgan system failure |
| 16 | 23 | 20/M | Crohn disease (prior thiopurine treatment) | Chemotherapy NOS | Unknown | Died of HSTCL |
| 17 | 23 | 18/M | Ulcerative colitis (prior thiopurine treatment) | Chemotherapy NOS | Unknown | Died of HSTCL |
| 18 | 23 | 23/M | Ulcerative colitis (prior thiopurine treatment) | Chemotherapy NOS | Unknown | Died of HSTCL |
| Patient number . | Reference . | Age (y)/sex . | Comorbidities . | Treatment . | Transplant type . | Outcome . |
|---|---|---|---|---|---|---|
| 1 | 14 | 10/M | None | HR BFM induction, CR Reinduction with IT MTX, vincristine, idarubicin, asparaginase, and dexamethasone after relapse 4 mo later | N/A | Alive |
| 2 | 15 | 5/F | Unknown | ICE + 1 additional unspecified line of therapy, AD | Allo, CR | Alive |
| 3 | 15 | 8/M | Unknown | ICE + 1 additional unspecified line of therapy, AD | Allo, CR | Relapsed at unknown time posttransplant Died of HSTCL |
| 4 | 15 | 9/M | Unknown | ICE + 1 additional unspecified line of therapy, CR | Allo, CR | Alive |
| 5 | 15 | 4/F | Unknown | ICE plus 1 additional unspecified line of therapy, CR | Allo, CR | Alive |
| 6 | 16 | 10/M | None | Inter-B-NHL 2010 Group C1 (no rituximab), AD ICE, AD GEM-P with daratumumab, AD UKALL regimen B, AD | N/A | Died of HSTCL |
| 7 | 17 | 10/F | None | 4-drug B-ALL induction followed by bendamustine and maintenance with lenalidomide and celecoxib, CR | N/A | Alive |
| 8 | 17 | 16/M | None | CHOEP, AD ICE + bortezomib, AD | N/A | Died of HSTCL |
| 9 | 18 | 3/F | History of short stature, microcephaly | Tokyo Children’s Cancer Study Group L09-1603 induction, AD FLAG, CR | Allo, CR | Alive |
| 10 | 19 | 3/F | History of mixed phenotype acute leukemia | ICE, alemtuzumab, radiation therapy, AD | N/A | Died at 107 d of follow-up |
| 11 | 19 | 4/M | None | None | N/A | Died |
| 12 | 19 | 21/M | None | ICE, CR | Allo, CR | Lost to follow-up after transplant |
| 13 | 20 | 17/F | None | Splenectomy, ICE, PD Pralatrexate-CHP, PR | Allo, CR | Died after transplant due to complications from human metapneumovirus pneumonia |
| 14 | 21 | 14/F | Turner syndrome, Crohn disease (prior 6-MP treatment) | ICE, CR | Allo, CR | Alive 1 y after transplant |
| 15 | 22 | 15/F | Crohn disease (prior 6-MP, MTX treatment) | ICE, PR | N/A | Died 2 mo after diagnosis of disseminated HSTCL and multiorgan system failure |
| 16 | 23 | 20/M | Crohn disease (prior thiopurine treatment) | Chemotherapy NOS | Unknown | Died of HSTCL |
| 17 | 23 | 18/M | Ulcerative colitis (prior thiopurine treatment) | Chemotherapy NOS | Unknown | Died of HSTCL |
| 18 | 23 | 23/M | Ulcerative colitis (prior thiopurine treatment) | Chemotherapy NOS | Unknown | Died of HSTCL |
6-MP: 6-mercaptopurine; AD, active disease; Allo, Allogeneic HSCT; B-ALL, B-cell acute lymphoblastic leukemia; BFM, Berlin-Frankfurt-Münster; CHOEP, cyclophosphamide, doxorubicin, vincristine, etoposide, prednisone; CHP, cyclophosphamide, doxorubicin, prednisone; F, female; FLAG, fludarabine, cytarabine, granulocyte colony-stimulating factor; GEM-P, gemcitabine, cisplatin and methylprednisolone; HR, high risk; IT, intrathecal; M, male; MTX, methotrexate; N/A, not applicable; NOS, not otherwise specified; PD, progressive disease; PR, partial response.